![]() | License: Creative Commons Attribution 4.0 PDF - Published Version (620kB) |
- URN to cite this document:
- urn:nbn:de:bvb:355-epub-530879
- DOI to cite this document:
- 10.5283/epub.53087
Abstract
Background: Adoptive therapy with genetically modified T cells achieves spectacular remissions in advanced hematologic malignancies. In contrast to conventional drugs, this kind of therapy applies viable autologous T cells that are ex vivo genetically engineered with a chimeric antigen receptor (CAR) and are classified as advanced therapy medicinal products. Summary: As “living drugs,” CAR T ...

Owner only: item control page